1. Skip to content
Posted on

Lilly says FDA widens use of cancer drug Alimta

Source: CNNMoney.com

Eli Lilly has announced that its cancer drug Alimta, when used in combination with cisplatin, has received FDA approval for the first-line treatment of “locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology.” The FDA’s new approval is the third overall approval that Alimta has received, and the second for its use in first-line therapy. The drug is most well known for the first-line treatment of pleural mesothelioma where it—again in combination with cisplatin—represents the chemotherapy standard of care for the treatment of the disease. It has also received approvals in single-agent use for the second-line treatment of NSCLC after prior chemotherapy treatment.

More articles by

Nancy Meredith is a blog and web content writer with more than 20 years of professional experience in the Information Technology industry. She has been writing about Mesothelioma for 7 years. Follow Nancy on Google+

Comments are closed.